Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes.
Ali M, Giannakopoulou E, Li Y, Lehander M, Virding Culleton S, Yang W, Knetter C, Odabasi MC, Bollineni RC, Yang X, Foldvari Z, Böschen ML, Taraldsrud E, Strønen E, Toebes M, Hillen A, Mazzi S, de Ru AH, Janssen GMC, Kolstad A, Tjønnfjord GE, Lie BA, Griffioen M, Lehmann S, Osnes LT, Buechner J, Garcia KC, Schumacher TN, van Veelen PA, Leisegang M, Jacobsen SEW, Woll P, Olweus J. Ali M, et al. Among authors: griffioen m. Nat Biotechnol. 2022 Apr;40(4):488-498. doi: 10.1038/s41587-021-01089-x. Epub 2021 Dec 6. Nat Biotechnol. 2022. PMID: 34873326 Free PMC article.
Acquisition of a glycosylated B-cell receptor drives follicular lymphoma toward a dark zone phenotype.
van Bergen CAM, Kloet SL, Quinten E, Sepúlveda Yáñez JH, Menafra R, Griffioen M, Jansen PM, Koning MT, Knijnenburg J, Navarrete MA, Kiełbasa SM, Veelken H. van Bergen CAM, et al. Among authors: griffioen m. Blood Adv. 2023 Oct 10;7(19):5812-5816. doi: 10.1182/bloodadvances.2023010725. Blood Adv. 2023. PMID: 37493974 Free PMC article. No abstract available.
PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.
Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, de Ru AH, Lugthart GJ, van Kooten C, Hiemstra PS, Jedema I, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH. Amir AL, et al. Among authors: griffioen m. Clin Cancer Res. 2011 Sep 1;17(17):5615-25. doi: 10.1158/1078-0432.CCR-11-1066. Epub 2011 Jul 19. Clin Cancer Res. 2011. PMID: 21771875
Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.
Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH. Hombrink P, et al. Among authors: griffioen m. Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589627
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH. Jahn L, et al. Among authors: griffioen m. Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4. Blood. 2017. PMID: 28053195 Free article.
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: griffioen m. J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14. J Clin Invest. 2019. PMID: 30640174 Free PMC article.
Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM.
Meurer T, Crivello P, Metzing M, Kester M, Megger DA, Chen W, van Veelen PA, van Balen P, Westendorf AM, Homa G, Layer SE, Turki AT, Griffioen M, Horn PA, Sitek B, Beelen DW, Falkenburg JHF, Arrieta-Bolaños E, Fleischhauer K. Meurer T, et al. Among authors: griffioen m. Blood. 2021 Feb 18;137(7):923-928. doi: 10.1182/blood.2020008464. Blood. 2021. PMID: 33025005 Free article.
Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.
de Waard AA, Verkerk T, Hoefakker K, van der Steen DM, Jongsma MLM, Melamed Kadosh D, Bliss S, de Ru AH, Admon A, van Veelen PA, Griffioen M, Heemskerk MHM, Spaapen RM. de Waard AA, et al. Among authors: griffioen m. iScience. 2021 Jan 9;24(2):102051. doi: 10.1016/j.isci.2021.102051. eCollection 2021 Feb 19. iScience. 2021. PMID: 33554062 Free PMC article.
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, Morton LT, van der Steen DM, Kweekel C, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: griffioen m. Mol Ther. 2022 Feb 2;30(2):564-578. doi: 10.1016/j.ymthe.2021.08.010. Epub 2021 Aug 8. Mol Ther. 2022. PMID: 34371177 Free PMC article.
119 results